ID   FGFR3_HUMAN             Reviewed;         806 AA.
AC   P22607; D3DVP9; D3DVQ0; Q14308; Q16294; Q16608; Q59FL9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   10-MAY-2017, entry version 219.
DE   RecName: Full=Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=FGFR3; Synonyms=JTK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1847508; DOI=10.1073/pnas.88.4.1095;
RA   Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
RT   "Isolation of an additional member of the fibroblast growth factor
RT   receptor family, FGFR-3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND
RP   FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION.
RC   TISSUE=Squamous cell carcinoma;
RX   PubMed=11703096; DOI=10.1006/mcbr.2001.0306;
RA   Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H.,
RA   Kurokawa-Seo M.;
RT   "Fibroblast growth factor receptor 3 lacking the Ig IIIb and
RT   transmembrane domains secreted from human squamous cell carcinoma DJM-
RT   1 binds to FGFs.";
RL   Mol. Cell Biol. Res. Commun. 4:365-373(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384;
RP   THR-441; THR-717 AND PHE-726.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=1664411; DOI=10.1016/0888-7543(91)90041-C;
RA   Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F.,
RA   Housman D.E., Wasmuth J.J.;
RT   "A gene encoding a fibroblast growth factor receptor isolated from the
RT   Huntington disease gene region of human chromosome 4.";
RL   Genomics 11:1133-1142(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Colon tumor;
RX   PubMed=7923141;
RA   Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
RT   "Identification of a novel variant form of fibroblast growth factor
RT   receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
RL   Cancer Res. 54:5206-5211(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Keratinocyte;
RX   PubMed=7495869; DOI=10.1016/0167-4781(95)00156-B;
RA   Scotet E., Houssaint E.;
RT   "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene
RT   is not strictly tissue-specific.";
RL   Biochim. Biophys. Acta 1264:238-242(1995).
RN   [11]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [12]
RP   INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF
RP   VARIANT SADDAN MET-650.
RX   PubMed=10053006; DOI=10.1086/302275;
RA   Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E.,
RA   McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J.,
RA   Donoghue D.J., Thompson L.M., Francomano C.A.;
RT   "A novel skeletal dysplasia with developmental delay and acanthosis
RT   nigricans is caused by a Lys650Met mutation in the fibroblast growth
RT   factor receptor 3 gene.";
RL   Am. J. Hum. Genet. 64:722-731(1999).
RN   [13]
RP   FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF
RP   SIGNALING PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION,
RP   AUTOPHOSPHORYLATION, AND CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=10611230; DOI=10.1128/MCB.20.2.516-522.2000;
RA   Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.;
RT   "The transmembrane mutation G380R in fibroblast growth factor receptor
RT   3 uncouples ligand-mediated receptor activation from down-
RT   regulation.";
RL   Mol. Cell. Biol. 20:516-522(2000).
RN   [14]
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF
RP   PIK3R1; PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT
RP   TYR-724, MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND
RP   CHARACTERIZATION OF VARIANT GLU-650.
RX   PubMed=11294897; DOI=10.1091/mbc.12.4.931;
RA   Hart K.C., Robertson S.C., Donoghue D.J.;
RT   "Identification of tyrosine residues in constitutively activated
RT   fibroblast growth factor receptor 3 involved in mitogenesis, Stat
RT   activation, and phosphatidylinositol 3-kinase activation.";
RL   Mol. Biol. Cell 12:931-942(2001).
RN   [15]
RP   UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION
RP   OF VARIANT TD2 GLU-650.
RX   PubMed=12297284; DOI=10.1016/S0014-5793(02)03255-6;
RA   Monsonego-Ornan E., Adar R., Rom E., Yayon A.;
RT   "FGF receptors ubiquitylation: dependence on tyrosine kinase activity
RT   and role in downregulation.";
RL   FEBS Lett. 528:83-89(2002).
RN   [16]
RP   FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION
RP   OF VARIANT GLU-650, AND AUTOPHOSPHORYLATION.
RX   PubMed=14534538; DOI=10.1038/sj.onc.1206798;
RA   Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.;
RT   "The phosphotyrosine phosphatase SHP2 is a critical mediator of
RT   transformation induced by the oncogenic fibroblast growth factor
RT   receptor 3.";
RL   Oncogene 22:6909-6918(2003).
RN   [17]
RP   INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [18]
RP   INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND
RP   MAP KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=16410555; DOI=10.1242/jcs.02740;
RA   Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
RT   "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with
RT   and modulate fibroblast growth factor receptor signaling.";
RL   J. Cell Sci. 119:380-387(2006).
RN   [19]
RP   FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION
RP   OF PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380;
RP   GLU-650 AND MET-650.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of
RT   genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell
RT   line via PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, ENZYME REGULATION, AND CHARACTERIZATION OF
RP   VARIANTS CYS-248; CYS-373 AND MET-650.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia
RT   type I differentially affects phosphorylation, processing and
RT   ubiquitylation of the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT
RP   GLU-650, ENZYME REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=17145761; DOI=10.1074/jbc.M606144200;
RA   Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H.,
RA   Thompson L.M., Wilcox W.R.;
RT   "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated
RT   activation of Erk MAP kinase in chondrocytes by preventing Shp2
RT   association with the Frs2 and Gab1 adaptor proteins.";
RL   J. Biol. Chem. 282:2929-2936(2007).
RN   [22]
RP   INTERACTION WITH FGF19; FGF21 AND KLB.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [23]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [24]
RP   FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE
RP   MAP KINASE SIGNALING PATHWAY.
RX   PubMed=19088846; DOI=10.1371/journal.pone.0003961;
RA   Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A.,
RA   Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.;
RT   "Analysis of STAT1 activation by six FGFR3 mutants associated with
RT   skeletal dysplasia undermines dominant role of STAT1 in FGFR3
RT   signaling in cartilage.";
RL   PLoS ONE 3:E3961-E3961(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT
RP   TYR-760.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and
RT   the p85 subunit of phosphoinositide 3-kinase: activation-dependent
RT   regulation of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [27]
RP   REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN
RP   DISEASE.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [28]
RP   REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN;
RP   ROLE IN DISEASE; UBIQUITINATION AND DEGRADATION.
RX   PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012;
RA   L'Hote C.G., Knowles M.A.;
RT   "Cell responses to FGFR3 signalling: growth, differentiation and
RT   apoptosis.";
RL   Exp. Cell Res. 304:417-431(2005).
RN   [29]
RP   REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE.
RX   PubMed=19066716; DOI=10.1007/s00774-008-0009-7;
RA   Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.;
RT   "FGFR3-related dwarfism and cell signaling.";
RL   J. Bone Miner. Metab. 27:9-15(2009).
RN   [30]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1,
RP   ENZYME REGULATION, AND DOMAIN.
RX   PubMed=14732692; DOI=10.1073/pnas.0307287101;
RA   Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V.,
RA   Yayon A., Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
RT   "Insights into the molecular basis for fibroblast growth factor
RT   receptor autoinhibition and ligand-binding promiscuity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
RN   [33]
RP   VARIANT ACH ARG-380.
RX   PubMed=8078586; DOI=10.1038/371252a0;
RA   Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M.,
RA   Maroteaux P., le Merrer M., Munnich A.;
RT   "Mutations in the gene encoding fibroblast growth factor receptor-3 in
RT   achondroplasia.";
RL   Nature 371:252-254(1994).
RN   [34]
RP   VARIANT ACH ARG-380.
RX   PubMed=7847369;
RA   Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A.,
RA   Machado M., Kaitila I., McIntosh I., Francomano C.A.;
RT   "Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
RL   Am. J. Hum. Genet. 56:368-373(1995).
RN   [35]
RP   VARIANT ACH CYS-375.
RX   PubMed=7758520; DOI=10.1007/BF01954274;
RA   Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A.,
RA   Gitzelmann R., Steinmann B.;
RT   "A glycine 375-to-cysteine substitution in the transmembrane domain of
RT   the fibroblast growth factor receptor-3 in a newborn with
RT   achondroplasia.";
RL   Eur. J. Pediatr. 154:215-219(1995).
RN   [36]
RP   VARIANT TD1 CYS-249.
RX   PubMed=8589699; DOI=10.1093/hmg/4.11.2175;
RA   Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R.,
RA   Wasmuth J.J.;
RT   "Another mutation that results in the substitution of an unpaired
RT   cysteine residue in the extracellular domain of FGFR3 in thanatophoric
RT   dysplasia type I.";
RL   Hum. Mol. Genet. 4:2175-2177(1995).
RN   [37]
RP   VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650.
RX   PubMed=7773297; DOI=10.1038/ng0395-321;
RA   Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J.,
RA   Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
RT   "Thanatophoric dysplasia (types I and II) caused by distinct mutations
RT   in fibroblast growth factor receptor 3.";
RL   Nat. Genet. 9:321-328(1995).
RN   [38]
RP   VARIANT HYPOCHONDROPLASIA LYS-540.
RX   PubMed=7670477; DOI=10.1038/ng0795-357;
RA   Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I.,
RA   Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
RT   "A recurrent mutation in the tyrosine kinase domain of fibroblast
RT   growth factor receptor 3 causes hypochondroplasia.";
RL   Nat. Genet. 10:357-359(1995).
RN   [39]
RP   VARIANT CAN GLU-391.
RX   PubMed=7493034; DOI=10.1038/ng1295-462;
RA   Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
RT   "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in
RT   Crouzon syndrome with acanthosis nigricans.";
RL   Nat. Genet. 11:462-464(1995).
RN   [40]
RP   CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=8599935;
RA   Webster M.K., Donoghue D.J.;
RT   "Constitutive activation of fibroblast growth factor receptor 3 by the
RT   transmembrane domain point mutation found in achondroplasia.";
RL   EMBO J. 15:520-527(1996).
RN   [41]
RP   VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373.
RX   PubMed=8845844; DOI=10.1093/hmg/5.4.509;
RA   Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L.,
RA   le Merrer M., Munnich A., Bonaventure J.;
RT   "Missense FGFR3 mutations create cysteine residues in thanatophoric
RT   dwarfism type I (TD1).";
RL   Hum. Mol. Genet. 5:509-512(1996).
RN   [42]
RP   CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT
RP   GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648.
RX   PubMed=8754806; DOI=10.1128/MCB.16.8.4081;
RA   Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.;
RT   "Profound ligand-independent kinase activation of fibroblast growth
RT   factor receptor 3 by the activation loop mutation responsible for a
RT   lethal skeletal dysplasia, thanatophoric dysplasia type II.";
RL   Mol. Cell. Biol. 16:4081-4087(1996).
RN   [43]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9042914;
RA   Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K.,
RA   Whitaker L.A., Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N.,
RA   Mulvihill J.J., Losken H.W., Mulliken J.B., Guttmacher A.E.,
RA   Wilroy R.S., Clarke L.A., Hollway G., Ades L.C., Haan E.A.,
RA   Mulley J.C., Cohen M.M. Jr., Bellus G.A., Francomano C.A.,
RA   Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
RT   "A unique point mutation in the fibroblast growth factor receptor 3
RT   gene (FGFR3) defines a new craniosynostosis syndrome.";
RL   Am. J. Hum. Genet. 60:555-564(1997).
RN   [44]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND
RP   MET-650.
RX   PubMed=9207791; DOI=10.1038/ng0797-260;
RA   Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M.,
RA   Bergsagel P.L.;
RT   "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
RT   associated with increased expression and activating mutations of
RT   fibroblast growth factor receptor 3.";
RL   Nat. Genet. 16:260-264(1997).
RN   [45]
RP   VARIANT TD1 CYS-370.
RX   PubMed=9790257; DOI=10.1507/endocrj.45.Suppl_S171;
RA   Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A.,
RA   Nimura A., Horikawa R., Tanaka T.;
RT   "G370C mutation in the FGFR3 gene in a Japanese patient with
RT   thanatophoric dysplasia.";
RL   Endocr. J. 45:S171-S174(1998).
RN   [46]
RP   VARIANT HYPOCHONDROPLASIA VAL-538.
RX   PubMed=10215410;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU17>3.0.CO;2-J;
RA   Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E.,
RA   Anvret M.;
RT   "A novel missense mutation Ile538Val in the fibroblast growth factor
RT   receptor 3 in hypochondroplasia.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [47]
RP   VARIANT HYPOCHONDROPLASIA THR-540.
RX   PubMed=9452043;
RA   Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M.,
RA   Bakker E.;
RT   "Asn540Thr substitution in the fibroblast growth factor receptor 3
RT   tyrosine kinase domain causing hypochondroplasia.";
RL   Hum. Mutat. Suppl. 1:S62-S65(1998).
RN   [48]
RP   VARIANT TD1 MET-650.
RX   PubMed=10671061;
RA   Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
RT   "Lys650Met substitution in the tyrosine kinase domain of the
RT   fibroblast growth factor receptor gene causes thanatophoric dysplasia
RT   type I.";
RL   Hum. Mutat. 12:362-363(1998).
RN   [49]
RP   VARIANT ARG-250.
RX   PubMed=9525367; DOI=10.1016/S0140-6736(98)24012-8;
RA   Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J.,
RA   Mulley J.C.;
RT   "Deafness due to Pro250Arg mutation of FGFR3.";
RL   Lancet 351:877-878(1998).
RN   [50]
RP   VARIANTS TD1 CYS-248; CYS-249 AND CYS-373.
RX   PubMed=10360402;
RX   DOI=10.1002/(SICI)1096-8628(19990611)84:5<476::AID-AJMG12>3.3.CO;2-O;
RA   Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B.,
RA   Wilcox W.R.;
RT   "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused
RT   by FGFR3 mutations.";
RL   Am. J. Med. Genet. 84:476-480(1999).
RN   [51]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9950359;
RA   Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J.,
RA   Renier D.;
RT   "Sex related expressivity of the phenotype in coronal craniosynostosis
RT   caused by the recurrent P250R FGFR3 mutation.";
RL   J. Med. Genet. 36:9-13(1999).
RN   [52]
RP   VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA
RP   CYS-248; CYS-249; CYS-370 AND GLU-650.
RX   PubMed=10471491; DOI=10.1038/12615;
RA   Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S.,
RA   Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
RT   "Frequent activating mutations of FGFR3 in human bladder and cervix
RT   carcinomas.";
RL   Nat. Genet. 23:18-20(1999).
RN   [53]
RP   VARIANT HYPOCHONDROPLASIA GLN-650.
RX   PubMed=11055896; DOI=10.1086/316892;
RA   Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T.,
RA   Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J.,
RA   Francomano C.A.;
RT   "Distinct missense mutations of the FGFR3 Lys650 codon modulate
RT   receptor kinase activation and the severity of the skeletal dysplasia
RT   phenotype.";
RL   Am. J. Hum. Genet. 67:1411-1421(2000).
RN   [54]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=10777366; DOI=10.1136/jmg.37.3.220;
RA   Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G.,
RA   De Paepe A.;
RT   "Clinical and radiographic features of a family with hypochondroplasia
RT   owing to a novel asn540ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   J. Med. Genet. 37:220-224(2000).
RN   [55]
RP   VARIANT MNKS ARG-250.
RX   PubMed=11746040; DOI=10.1002/ajmg.10049;
RA   Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
RT   "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and
RT   sprengel shoulder with and without Pro250Arg mutation in the FGFR3
RT   gene.";
RL   Am. J. Med. Genet. 104:112-119(2001).
RN   [56]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
RX   PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x;
RA   Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T.,
RA   Neri A.;
RT   "Analysis of FGFR3 gene mutations in multiple myeloma patients with
RT   t(4;14).";
RL   Br. J. Haematol. 114:362-364(2001).
RN   [57]
RP   VARIANT COLORECTAL CANCER LYS-322.
RX   PubMed=11325814;
RA   Jang J.-H., Shin K.-H., Park J.-G.;
RT   "Mutations in fibroblast growth factor receptor 2 and fibroblast
RT   growth factor receptor 3 genes associated with human gastric and
RT   colorectal cancers.";
RL   Cancer Res. 61:3541-3543(2001).
RN   [58]
RP   VARIANT BLC CANCER GLN-650.
RX   PubMed=11314002; DOI=10.1038/sj.onc.1204110;
RA   Sibley K., Cuthbert-Heavens D., Knowles M.A.;
RT   "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in
RT   transitional cell carcinoma.";
RL   Oncogene 20:686-691(2001).
RN   [59]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=12707965; DOI=10.1002/ajmg.a.10238;
RA   Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V.,
RA   Francois C., Huet F., Couailler J.-F., Campos-Xavier A.B.,
RA   Bonaventure J., Le Merrer M.;
RT   "Hypochondroplasia and stature within normal limits: another family
RT   with an Asn540-to-Ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   Am. J. Med. Genet. A 119:81-84(2003).
RN   [60]
RP   VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650
RP   AND MET-650.
RX   PubMed=15772091; DOI=10.1093/hmg/ddi127;
RA   Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M.,
RA   Ribeiro A., Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X.,
RA   Thiery J.P., Radvanyi F.;
RT   "Activating mutations of the tyrosine kinase receptor FGFR3 are
RT   associated with benign skin tumors in mice and humans.";
RL   Hum. Mol. Genet. 14:1153-1160(2005).
RN   [61]
RP   VARIANT CATSHLS HIS-621.
RX   PubMed=17033969; DOI=10.1086/508433;
RA   Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A.,
RA   Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C.,
RA   Bamshad M.J.;
RT   "A novel mutation in FGFR3 causes camptodactyly, tall stature, and
RT   hearing loss (CATSHL) syndrome.";
RL   Am. J. Hum. Genet. 79:935-941(2006).
RN   [62]
RP   VARIANTS KNEN CYS-248; CYS-370 AND ARG-380.
RX   PubMed=16841094; DOI=10.1172/JCI28163;
RA   Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R.,
RA   Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A.;
RT   "Mosaicism of activating FGFR3 mutations in human skin causes
RT   epidermal nevi.";
RL   J. Clin. Invest. 116:2201-2207(2006).
RN   [63]
RP   VARIANT LADDS ASN-513.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [64]
RP   VARIANT CAN GLU-391.
RX   PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x;
RA   Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
RT   "Crouzon with acanthosis nigricans. Further delineation of the
RT   syndrome.";
RL   Clin. Genet. 72:405-410(2007).
RN   [65]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384;
RP   ASN-646 AND GLU-650.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [66]
RP   VARIANT TGCT GLU-650.
RX   PubMed=19855393; DOI=10.1038/ng.470;
RA   Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K.,
RA   McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E.,
RA   Wilkie A.O.;
RT   "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin
RT   for congenital disorders and testicular tumors.";
RL   Nat. Genet. 41:1247-1252(2009).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays an essential role
CC       in the regulation of cell proliferation, differentiation and
CC       apoptosis. Plays an essential role in the regulation of
CC       chondrocyte differentiation, proliferation and apoptosis, and is
CC       required for normal skeleton development. Regulates both
CC       osteogenesis and postnatal bone mineralization by osteoblasts.
CC       Promotes apoptosis in chondrocytes, but can also promote cancer
CC       cell proliferation. Required for normal development of the inner
CC       ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to
CC       the activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Plays a role in the regulation of vitamin D metabolism.
CC       Mutations that lead to constitutive kinase activation or impair
CC       normal FGFR3 maturation, internalization and degradation lead to
CC       aberrant signaling. Over-expressed or constitutively activated
CC       FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and
CC       STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and
CC       FGF2 and hence may interfere with FGF signaling.
CC       {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897,
CC       ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:17145761}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues. Inhibited
CC       by SU5402. {ECO:0000269|PubMed:14732692,
CC       ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17509076}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with
CC       FGF1, FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19,
CC       FGF20 and FGF23 (in vitro). Interacts with KLB. Affinity for
CC       fibroblast growth factors (FGFs) is increased by heparan sulfate
CC       glycosaminoglycans that function as coreceptors. Likewise, KLB
CC       increases the affinity for FGF19 and FGF21. Interacts with PIK3R1,
CC       PLCG1, SOCS1 and SOCS3. Isoform 3 forms disulfide-linked dimers.
CC       {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11703096,
CC       ECO:0000269|PubMed:14732692, ECO:0000269|PubMed:16410555,
CC       ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P05230:FGF1; NbExp=3; IntAct=EBI-348399, EBI-698068;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-348399, EBI-352572;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum.
CC       Note=The activated receptor is rapidly internalized and degraded.
CC       Detected in intracellular vesicles after internalization of the
CC       autophosphorylated receptor.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane {ECO:0000250};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cell membrane {ECO:0000250};
CC       Single-pass type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=P22607-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=P22607-2; Sequence=VSP_002988;
CC       Name=3; Synonyms=FGFR3deltaTM;
CC         IsoId=P22607-3; Sequence=VSP_002989;
CC       Name=4;
CC         IsoId=P22607-4; Sequence=VSP_040945;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very
CC       low or no expression in spleen, heart, and muscle. In 20- to 22-
CC       week old fetuses it is expressed at high level in kidney, lung,
CC       small intestine and brain, and to a lower degree in spleen, liver,
CC       and muscle. Isoform 2 is detected in epithelial cells. Isoform 1
CC       is not detected in epithelial cells. Isoform 1 and isoform 2 are
CC       detected in fibroblastic cells. {ECO:0000269|PubMed:1664411}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact
CC       with fibroblast growth factors (FGF) and heparan sulfate
CC       proteoglycans. {ECO:0000269|PubMed:14732692}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. Phosphorylation at Tyr-724 is essential for
CC       stimulation of cell proliferation and activation of PIK3R1, STAT1
CC       and MAP kinase signaling. Phosphorylation at Tyr-760 is required
CC       for interaction with PIK3R1 and PLCG1.
CC       {ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:19286672}.
CC   -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding
CC       and autophosphorylation, leading to receptor internalization and
CC       degradation. Subject to both proteasomal and lysosomal
CC       degradation. {ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:17509076}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan
CC       chains undergo further maturation to an Endo H-resistant form in
CC       the Golgi apparatus. {ECO:0000269|PubMed:11703096,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17509076}.
CC   -!- DISEASE: Achondroplasia (ACH) [MIM:100800]: A frequent form of
CC       short-limb dwarfism. It is characterized by a long, narrow trunk,
CC       short extremities, particularly in the proximal (rhizomelic)
CC       segments, a large head with frontal bossing, hypoplasia of the
CC       midface and a trident configuration of the hands.
CC       {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:7758520, ECO:0000269|PubMed:7847369,
CC       ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Crouzon syndrome with acanthosis nigricans (CAN)
CC       [MIM:612247]: Classic Crouzon disease which is caused by mutations
CC       in the FGFR2 gene is characterized by craniosynostosis (premature
CC       fusion of the skull sutures), and facial hypoplasia. Crouzon
CC       syndrome with acanthosis nigricans (a skin disorder characterized
CC       by pigmentation anomalies), CAN, is considered to be an
CC       independent disorder from classic Crouzon syndrome. CAN is
CC       characterized by additional more severe physical manifestation,
CC       such as Chiari malformation, hydrocephalus, and atresia or
CC       stenosis of the choanas, and is caused by a specific mutation
CC       (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is
CC       proposed to have an autosomal dominant mode of inheritance.
CC       {ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Thanatophoric dysplasia 1 (TD1) [MIM:187600]: A neonatal
CC       lethal skeletal dysplasia. Affected individuals manifest severe
CC       shortening of the limbs with macrocephaly, narrow thorax, short
CC       ribs, and curved femurs. {ECO:0000269|PubMed:10360402,
CC       ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:7773297,
CC       ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844,
CC       ECO:0000269|PubMed:9790257}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Thanatophoric dysplasia 2 (TD2) [MIM:187601]: A neonatal
CC       lethal skeletal dysplasia causing severe shortening of the limbs,
CC       narrow thorax and short ribs. Patients with thanatophoric
CC       dysplasia type 2 have straight femurs and cloverleaf skull.
CC       {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:7773297,
CC       ECO:0000269|PubMed:8754806}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypochondroplasia (HCH) [MIM:146000]: Autosomal dominant
CC       disease and is characterized by disproportionate short stature. It
CC       resembles achondroplasia, but with a less severe phenotype.
CC       {ECO:0000269|PubMed:10215410, ECO:0000269|PubMed:10777366,
CC       ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:12707965,
CC       ECO:0000269|PubMed:7670477, ECO:0000269|PubMed:9452043}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy
CC       originating in tissues of the urinary bladder. It often presents
CC       with multiple tumors appearing at different times and at different
CC       sites in the bladder. Most bladder cancers are transitional cell
CC       carcinomas that begin in cells that normally make up the inner
CC       lining of the bladder. Other types of bladder cancer include
CC       squamous cell carcinoma (cancer that begins in thin, flat cells)
CC       and adenocarcinoma (cancer that begins in cells that make and
CC       release mucus and other fluids). Bladder cancer is a complex
CC       disorder with both genetic and environmental influences.
CC       {ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11314002}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry. Somatic mutations
CC       can constitutively activate FGFR3.
CC   -!- DISEASE: Cervical cancer (CERCA) [MIM:603956]: A malignant
CC       neoplasm of the cervix, typically originating from a dysplastic or
CC       premalignant lesion previously present at the active
CC       squamocolumnar junction. The transformation from mild dysplastic
CC       to invasive carcinoma generally occurs slowly within several
CC       years, although the rate of this process varies widely. Carcinoma
CC       in situ is particularly known to precede invasive cervical cancer
CC       in most cases. Cervical cancer is strongly associated with
CC       infection by oncogenic types of human papillomavirus.
CC       {ECO:0000269|PubMed:10471491}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Camptodactyly, tall stature, and hearing loss syndrome
CC       (CATSHLS) [MIM:610474]: An autosomal dominant syndrome
CC       characterized by permanent and irreducible flexion of one or more
CC       fingers of the hand and/or feet, tall stature, scoliosis and/or a
CC       pectus excavatum, and hearing loss. Affected individuals have
CC       developmental delay and/or mental retardation, and several of
CC       these have microcephaly. Radiographic findings included tall
CC       vertebral bodies with irregular borders and broad femoral
CC       metaphyses with long tubular shafts. On audiological exam, each
CC       tested member have bilateral sensorineural hearing loss and absent
CC       otoacoustic emissions. The hearing loss was congenital or
CC       developed in early infancy, progressed variably in early
CC       childhood, and range from mild to severe. Computed tomography and
CC       magnetic resonance imaging reveal that the brain, middle ear, and
CC       inner ear are structurally normal. {ECO:0000269|PubMed:17033969}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of
CC       plasma cells usually arising in the bone marrow and characterized
CC       by diffuse involvement of the skeletal system, hyperglobulinemia,
CC       Bence-Jones proteinuria and anemia. Complications of multiple
CC       myeloma are bone pain, hypercalcemia, renal failure and spinal
CC       cord compression. The aberrant antibodies that are produced lead
CC       to impaired humoral immunity and patients have a high prevalence
CC       of infection. Amyloidosis may develop in some patients. Multiple
CC       myeloma is part of a spectrum of diseases ranging from monoclonal
CC       gammopathy of unknown significance (MGUS) to plasma cell leukemia.
CC       {ECO:0000269|PubMed:11529856, ECO:0000269|PubMed:9207791}.
CC       Note=The gene represented in this entry may be involved in disease
CC       pathogenesis. A chromosomal aberration involving FGFR3 is found in
CC       multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH
CC       locus.
CC   -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS)
CC       [MIM:149730]: An autosomal dominant ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. Lacrimo-auriculo-dento-digital
CC       syndrome is characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed. {ECO:0000269|PubMed:16501574}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN)
CC       [MIM:162900]: Epidermal nevi of the common, non-organoid and non-
CC       epidermolytic type are benign skin lesions and may vary in their
CC       extent from a single (usually linear) lesion to widespread and
CC       systematized involvement. They may be present at birth or develop
CC       early during childhood. {ECO:0000269|PubMed:16841094}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Muenke syndrome (MNKS) [MIM:602849]: A condition
CC       characterized by premature closure of coronal suture of skull
CC       during development (coronal craniosynostosis), which affects the
CC       shape of the head and face. It may be uni- or bilateral. When
CC       bilateral, it is characterized by a skull with a small antero-
CC       posterior diameter (brachycephaly), often with a decrease in the
CC       depth of the orbits and hypoplasia of the maxillae. Unilateral
CC       closure of the coronal sutures leads to flattening of the orbit on
CC       the involved side (plagiocephaly). The intellect is normal. In
CC       addition to coronal craniosynostosis some affected individuals
CC       show skeletal abnormalities of hands and feet, sensorineural
CC       hearing loss, mental retardation and respiratory insufficiency.
CC       {ECO:0000269|PubMed:11746040, ECO:0000269|PubMed:9042914,
CC       ECO:0000269|PubMed:9950359}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common
CC       benign skin tumor. Seborrheic keratoses usually begin with the
CC       appearance of one or more sharply defined, light brown, flat
CC       macules. The lesions may be sparse or numerous. As they initially
CC       grow, they develop a velvety to finely verrucous surface, followed
CC       by an uneven warty surface with multiple plugged follicles and a
CC       dull or lackluster appearance. {ECO:0000269|PubMed:15772091}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
CC       {ECO:0000269|PubMed:19855393}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis.
CC   -!- DISEASE: Achondroplasia, severe, with developmental delay and
CC       acanthosis nigricans (SADDAN) [MIM:616482]: A severe form of
CC       achondroplasia associated with developmental delay and acanthosis
CC       nigricans. Patients manifest short-limb dwarfism, with a long,
CC       narrow trunk, short extremities, particularly in the proximal
CC       (rhizomelic) segments, a large head with frontal bossing,
CC       hypoplasia of the midface and a trident configuration of the
CC       hands. Acanthosis nigricans is a skin condition characterized by
CC       brown-pigmented, velvety verrucosities in body folds and creases.
CC       {ECO:0000269|PubMed:10053006}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92678.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFRID99.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58051; AAA52450.1; -; mRNA.
DR   EMBL; AF245114; AAF63380.1; -; mRNA.
DR   EMBL; AB209441; BAD92678.1; ALT_INIT; mRNA.
DR   EMBL; AY768549; AAU89726.1; -; Genomic_DNA.
DR   EMBL; AC016773; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471131; EAW82564.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82565.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82566.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82567.1; -; Genomic_DNA.
DR   EMBL; M64347; AAA58470.1; -; mRNA.
DR   EMBL; M59374; AAA63209.1; -; mRNA.
DR   EMBL; S76733; AAB33323.1; -; Genomic_DNA.
DR   EMBL; X84939; CAA59334.1; -; mRNA.
DR   EMBL; U22410; AAA67781.1; -; Genomic_DNA.
DR   CCDS; CCDS3353.1; -. [P22607-1]
DR   CCDS; CCDS3354.1; -. [P22607-3]
DR   CCDS; CCDS54706.1; -. [P22607-2]
DR   PIR; A38576; TVHUF3.
DR   RefSeq; NP_000133.1; NM_000142.4. [P22607-1]
DR   RefSeq; NP_001156685.1; NM_001163213.1. [P22607-2]
DR   RefSeq; NP_075254.1; NM_022965.3. [P22607-3]
DR   UniGene; Hs.1420; -.
DR   PDB; 1RY7; X-ray; 3.20 A; B=33-365.
DR   PDB; 2LZL; NMR; -; A/B=357-399.
DR   PDB; 4K33; X-ray; 2.34 A; A=449-759.
DR   PDBsum; 1RY7; -.
DR   PDBsum; 2LZL; -.
DR   PDBsum; 4K33; -.
DR   ProteinModelPortal; P22607; -.
DR   SMR; P22607; -.
DR   BioGrid; 108552; 43.
DR   DIP; DIP-4016N; -.
DR   IntAct; P22607; 27.
DR   MINT; MINT-1034697; -.
DR   STRING; 9606.ENSP00000339824; -.
DR   BindingDB; P22607; -.
DR   ChEMBL; CHEMBL2742; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB05014; XL999.
DR   GuidetoPHARMACOLOGY; 1810; -.
DR   iPTMnet; P22607; -.
DR   PhosphoSitePlus; P22607; -.
DR   BioMuta; FGFR3; -.
DR   DMDM; 120050; -.
DR   PaxDb; P22607; -.
DR   PeptideAtlas; P22607; -.
DR   PRIDE; P22607; -.
DR   DNASU; 2261; -.
DR   Ensembl; ENST00000260795; ENSP00000260795; ENSG00000068078. [P22607-1]
DR   Ensembl; ENST00000340107; ENSP00000339824; ENSG00000068078. [P22607-2]
DR   Ensembl; ENST00000352904; ENSP00000231803; ENSG00000068078. [P22607-3]
DR   Ensembl; ENST00000412135; ENSP00000412903; ENSG00000068078. [P22607-3]
DR   Ensembl; ENST00000440486; ENSP00000414914; ENSG00000068078. [P22607-1]
DR   GeneID; 2261; -.
DR   KEGG; hsa:2261; -.
DR   UCSC; uc003gdr.3; human. [P22607-1]
DR   CTD; 2261; -.
DR   DisGeNET; 2261; -.
DR   GeneCards; FGFR3; -.
DR   GeneReviews; FGFR3; -.
DR   HGNC; HGNC:3690; FGFR3.
DR   HPA; CAB004231; -.
DR   HPA; HPA067204; -.
DR   MalaCards; FGFR3; -.
DR   MIM; 100800; phenotype.
DR   MIM; 109800; phenotype.
DR   MIM; 134934; gene.
DR   MIM; 146000; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 162900; phenotype.
DR   MIM; 182000; phenotype.
DR   MIM; 187600; phenotype.
DR   MIM; 187601; phenotype.
DR   MIM; 254500; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 602849; phenotype.
DR   MIM; 603956; phenotype.
DR   MIM; 610474; phenotype.
DR   MIM; 612247; phenotype.
DR   MIM; 616482; phenotype.
DR   neXtProt; NX_P22607; -.
DR   OpenTargets; ENSG00000068078; -.
DR   Orphanet; 15; Achondroplasia.
DR   Orphanet; 85164; Camptodactyly - tall stature - scoliosis - hearing loss.
DR   Orphanet; 93262; Crouzon syndrome - acanthosis nigricans.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 429; Hypochondroplasia.
DR   Orphanet; 35099; Isolated brachycephaly.
DR   Orphanet; 35098; Isolated plagiocephaly.
DR   Orphanet; 2363; Lacrimoauriculodentodigital syndrome.
DR   Orphanet; 53271; Muenke syndrome.
DR   Orphanet; 794; Saethre-Chotzen syndrome.
DR   Orphanet; 85165; Severe achondroplasia - developmental delay - acanthosis nigricans.
DR   Orphanet; 1860; Thanatophoric dysplasia type 1.
DR   Orphanet; 93274; Thanatophoric dysplasia type 2.
DR   PharmGKB; PA28129; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P22607; -.
DR   KO; K05094; -.
DR   OMA; SFDTCKP; -.
DR   OrthoDB; EOG091G0CQZ; -.
DR   PhylomeDB; P22607; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839130; Signaling by activated point mutants of FGFR3.
DR   Reactome; R-HSA-190371; FGFR3b ligand binding and activation.
DR   Reactome; R-HSA-190372; FGFR3c ligand binding and activation.
DR   Reactome; R-HSA-2033514; FGFR3 mutant receptor activation.
DR   Reactome; R-HSA-2033515; t(4;14) translocations of FGFR3.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   SignaLink; P22607; -.
DR   SIGNOR; P22607; -.
DR   ChiTaRS; FGFR3; human.
DR   EvolutionaryTrace; P22607; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_3; -.
DR   GenomeRNAi; 2261; -.
DR   PRO; PR:P22607; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000068078; -.
DR   CleanEx; HS_FGFR3; -.
DR   ExpressionAtlas; P22607; baseline and differential.
DR   Genevisible; P22607; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IMP:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0070977; P:bone maturation; ISS:BHF-UCL.
DR   GO; GO:0030282; P:bone mineralization; ISS:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0035988; P:chondrocyte proliferation; TAS:UniProtKB.
DR   GO; GO:0003416; P:endochondral bone growth; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; TAS:UniProtKB.
DR   GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0048640; P:negative regulation of developmental growth; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR028176; FGF_rcpt_3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   PANTHER; PTHR24416:SF401; PTHR24416:SF401; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Craniosynostosis; Cytoplasmic vesicle; Deafness; Disease mutation;
KW   Disulfide bond; Dwarfism; Ectodermal dysplasia; Endoplasmic reticulum;
KW   Glycoprotein; Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     22
FT   CHAIN        23    806       Fibroblast growth factor receptor 3.
FT                                /FTId=PRO_0000016785.
FT   TOPO_DOM     23    375       Extracellular. {ECO:0000255}.
FT   TRANSMEM    376    396       Helical. {ECO:0000255}.
FT   TOPO_DOM    397    806       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       24    126       Ig-like C2-type 1.
FT   DOMAIN      151    244       Ig-like C2-type 2.
FT   DOMAIN      253    355       Ig-like C2-type 3.
FT   DOMAIN      472    761       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     478    486       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    617    617       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     508    508       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     444    444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61851}.
FT   MOD_RES     445    445       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61851}.
FT   MOD_RES     647    647       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8754806}.
FT   MOD_RES     648    648       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8754806}.
FT   MOD_RES     724    724       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MOD_RES     760    760       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19286672}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    225    225       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    262    262       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    294    294       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    315    315       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    328    328       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     61    109       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    176    228       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    275    339       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     311    422       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11703096}.
FT                                /FTId=VSP_002989.
FT   VAR_SEQ     311    358       TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHS
FT                                AWLVVLP -> SWISESVEADVRLRLANVSERDGGEYLCRA
FT                                TNFIGVAEKAFWLSVHGPRA (in isoform 2).
FT                                {ECO:0000303|PubMed:7495869}.
FT                                /FTId=VSP_002988.
FT   VAR_SEQ     654    806       GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSP
FT                                YPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAP
FT                                SQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQD
FT                                TPSSSSSGDDSVFAHDLLPPAPPSSGGSRT -> LVLWGPA
FT                                LGDLHAGGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVH
FT                                DHAGVLACRALPEAHLQAAGGGPGPCPYRDVHRRVPGPVGA
FT                                FRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADV
FT                                KGHWSPTM (in isoform 4).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_040945.
FT   VARIANT      65     65       G -> R (in dbSNP:rs2305178).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022167.
FT   VARIANT      79     79       T -> S (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042207.
FT   VARIANT     228    228       C -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042208.
FT   VARIANT     248    248       R -> C (in KERSEB, BLC, keratinocytic
FT                                non-epidermolytic nevus and TD1; severe
FT                                and lethal; also found as somatic
FT                                mutation in one patient with multiple
FT                                myeloma; constitutive dimerization and
FT                                kinase activation; dbSNP:rs121913482).
FT                                {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:11529856,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:7773297,
FT                                ECO:0000269|PubMed:8845844}.
FT                                /FTId=VAR_004148.
FT   VARIANT     249    249       S -> C (in KERSEB, BLC, cervical cancer
FT                                and TD1; dbSNP:rs121913483).
FT                                {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:8589699,
FT                                ECO:0000269|PubMed:8845844}.
FT                                /FTId=VAR_004149.
FT   VARIANT     250    250       P -> R (in MNKS; also some individuals
FT                                with autosomal dominant congenital
FT                                sensorineural deafness without
FT                                craniosynostosis; dbSNP:rs4647924).
FT                                {ECO:0000269|PubMed:11746040,
FT                                ECO:0000269|PubMed:9042914,
FT                                ECO:0000269|PubMed:9525367,
FT                                ECO:0000269|PubMed:9950359}.
FT                                /FTId=VAR_004150.
FT   VARIANT     322    322       E -> K (in colorectal cancer;
FT                                dbSNP:rs121913111).
FT                                {ECO:0000269|PubMed:11325814}.
FT                                /FTId=VAR_018388.
FT   VARIANT     338    338       T -> M. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042209.
FT   VARIANT     370    370       G -> C (in KERSEB, BLC, keratinocytic
FT                                non-epidermolytic nevus and TD1;
FT                                dbSNP:rs121913479).
FT                                {ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:8845844,
FT                                ECO:0000269|PubMed:9790257}.
FT                                /FTId=VAR_004151.
FT   VARIANT     371    371       S -> C (in KERSEB and TD1;
FT                                dbSNP:rs121913484).
FT                                {ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:7773297}.
FT                                /FTId=VAR_004152.
FT   VARIANT     373    373       Y -> C (in KERSEB and TD1; disulfide-
FT                                linked dimer with constitutive kinase
FT                                activation; dbSNP:rs121913485).
FT                                {ECO:0000269|PubMed:10360402,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:8845844,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004153.
FT   VARIANT     375    375       G -> C (in ACH; dbSNP:rs75790268).
FT                                {ECO:0000269|PubMed:7758520}.
FT                                /FTId=VAR_004154.
FT   VARIANT     380    380       G -> R (in keratinocytic non-
FT                                epidermolytic nevus and ACH; very common
FT                                mutation; constitutively activated kinase
FT                                with impaired internalization and
FT                                degradation, resulting in prolonged FGFR3
FT                                signaling; dbSNP:rs28931614).
FT                                {ECO:0000269|PubMed:10611230,
FT                                ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:16841094,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:7847369,
FT                                ECO:0000269|PubMed:8078586,
FT                                ECO:0000269|PubMed:8599935}.
FT                                /FTId=VAR_004155.
FT   VARIANT     384    384       F -> L (in dbSNP:rs17881656).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022168.
FT   VARIANT     391    391       A -> E (in CAN; dbSNP:rs28931615).
FT                                {ECO:0000269|PubMed:17935505,
FT                                ECO:0000269|PubMed:7493034}.
FT                                /FTId=VAR_004156.
FT   VARIANT     441    441       A -> T (in dbSNP:rs17884368).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022169.
FT   VARIANT     513    513       D -> N (in LADDS; dbSNP:rs121913112).
FT                                {ECO:0000269|PubMed:16501574}.
FT                                /FTId=VAR_029887.
FT   VARIANT     538    538       I -> V (in hypochondroplasia;
FT                                dbSNP:rs80053154).
FT                                {ECO:0000269|PubMed:10215410}.
FT                                /FTId=VAR_004157.
FT   VARIANT     540    540       N -> K (in hypochondroplasia;
FT                                dbSNP:rs28933068).
FT                                {ECO:0000269|PubMed:7670477}.
FT                                /FTId=VAR_004158.
FT   VARIANT     540    540       N -> S (in hypochondroplasia; mild;
FT                                dbSNP:rs77722678).
FT                                {ECO:0000269|PubMed:10777366,
FT                                ECO:0000269|PubMed:12707965}.
FT                                /FTId=VAR_018389.
FT   VARIANT     540    540       N -> T (in hypochondroplasia;
FT                                dbSNP:rs77722678).
FT                                {ECO:0000269|PubMed:9452043}.
FT                                /FTId=VAR_004159.
FT   VARIANT     621    621       R -> H (in CATSHLS; dbSNP:rs121913113).
FT                                {ECO:0000269|PubMed:17033969}.
FT                                /FTId=VAR_029108.
FT   VARIANT     646    646       D -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042210.
FT   VARIANT     650    650       K -> E (in KERSEB, TD2, TGCT and BLC;
FT                                bladder transitional cell carcinoma;
FT                                somatic mutation; constitutively
FT                                activated kinase with impaired
FT                                internalization and degradation,
FT                                resulting in prolonged FGFR3 signaling;
FT                                dbSNP:rs78311289).
FT                                {ECO:0000269|PubMed:10471491,
FT                                ECO:0000269|PubMed:11294897,
FT                                ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:14534538,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17145761,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:19855393,
FT                                ECO:0000269|PubMed:7773297,
FT                                ECO:0000269|PubMed:8754806,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004160.
FT   VARIANT     650    650       K -> M (in KERSEB, ACH, TD1 and SADDAN;
FT                                constitutively activated kinase with
FT                                impaired internalization and degradation,
FT                                resulting in prolonged FGFR3 signaling;
FT                                dbSNP:rs121913105).
FT                                {ECO:0000269|PubMed:10053006,
FT                                ECO:0000269|PubMed:10671061,
FT                                ECO:0000269|PubMed:15772091,
FT                                ECO:0000269|PubMed:17509076,
FT                                ECO:0000269|PubMed:17561467,
FT                                ECO:0000269|PubMed:9207791}.
FT                                /FTId=VAR_004161.
FT   VARIANT     650    650       K -> Q (in hypochondroplasia and BLC; in
FT                                hypochondroplasia the form is milder than
FT                                that seen in individuals with the K-540
FT                                or M-650 mutations; constitutively
FT                                activated kinase; dbSNP:rs78311289).
FT                                {ECO:0000269|PubMed:11055896,
FT                                ECO:0000269|PubMed:11314002,
FT                                ECO:0000269|PubMed:8754806}.
FT                                /FTId=VAR_018390.
FT   VARIANT     717    717       A -> T (in dbSNP:rs17882190).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022170.
FT   VARIANT     726    726       I -> F (in dbSNP:rs17880763).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022171.
FT   MUTAGEN     508    508       K->A: Loss of kinase activity. Abolishes
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:12297284,
FT                                ECO:0000269|PubMed:16410555}.
FT   MUTAGEN     577    577       Y->F: Minor effect on kinase activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     650    650       K->D: Constitutively activated kinase.
FT   MUTAGEN     650    650       K->L: Constitutively activated kinase.
FT   MUTAGEN     724    724       Y->F: Strongly reduced kinase activity.
FT                                Strongly reduced mitogen activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     760    760       Y->F: Minor effect on kinase activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   MUTAGEN     770    770       Y->F: Minor effect on kinase activity.
FT                                Increased mitogen activity.
FT                                {ECO:0000269|PubMed:11294897}.
FT   CONFLICT    395    395       L -> V (in Ref. 7; AAA58470).
FT                                {ECO:0000305}.
FT   CONFLICT    421    421       R -> RQ (in Ref. 3; BAD92678).
FT                                {ECO:0000305}.
FT   STRAND      163    167       {ECO:0000244|PDB:1RY7}.
FT   STRAND      172    175       {ECO:0000244|PDB:1RY7}.
FT   STRAND      185    187       {ECO:0000244|PDB:1RY7}.
FT   TURN        208    211       {ECO:0000244|PDB:1RY7}.
FT   STRAND      212    215       {ECO:0000244|PDB:1RY7}.
FT   HELIX       220    222       {ECO:0000244|PDB:1RY7}.
FT   STRAND      226    232       {ECO:0000244|PDB:1RY7}.
FT   STRAND      235    246       {ECO:0000244|PDB:1RY7}.
FT   STRAND      263    268       {ECO:0000244|PDB:1RY7}.
FT   STRAND      271    273       {ECO:0000244|PDB:1RY7}.
FT   STRAND      283    289       {ECO:0000244|PDB:1RY7}.
FT   HELIX       293    295       {ECO:0000244|PDB:1RY7}.
FT   STRAND      302    304       {ECO:0000244|PDB:1RY7}.
FT   STRAND      324    326       {ECO:0000244|PDB:1RY7}.
FT   STRAND      335    345       {ECO:0000244|PDB:1RY7}.
FT   STRAND      348    357       {ECO:0000244|PDB:1RY7}.
FT   STRAND      369    372       {ECO:0000244|PDB:2LZL}.
FT   HELIX       374    398       {ECO:0000244|PDB:2LZL}.
FT   TURN        463    465       {ECO:0000244|PDB:4K33}.
FT   HELIX       469    471       {ECO:0000244|PDB:4K33}.
FT   STRAND      472    480       {ECO:0000244|PDB:4K33}.
FT   STRAND      482    496       {ECO:0000244|PDB:4K33}.
FT   STRAND      503    510       {ECO:0000244|PDB:4K33}.
FT   HELIX       516    532       {ECO:0000244|PDB:4K33}.
FT   STRAND      541    545       {ECO:0000244|PDB:4K33}.
FT   STRAND      547    550       {ECO:0000244|PDB:4K33}.
FT   STRAND      552    556       {ECO:0000244|PDB:4K33}.
FT   HELIX       563    568       {ECO:0000244|PDB:4K33}.
FT   HELIX       591    610       {ECO:0000244|PDB:4K33}.
FT   HELIX       620    622       {ECO:0000244|PDB:4K33}.
FT   STRAND      623    625       {ECO:0000244|PDB:4K33}.
FT   STRAND      631    633       {ECO:0000244|PDB:4K33}.
FT   STRAND      646    649       {ECO:0000244|PDB:4K33}.
FT   HELIX       658    660       {ECO:0000244|PDB:4K33}.
FT   HELIX       663    668       {ECO:0000244|PDB:4K33}.
FT   HELIX       673    688       {ECO:0000244|PDB:4K33}.
FT   HELIX       700    708       {ECO:0000244|PDB:4K33}.
FT   HELIX       721    730       {ECO:0000244|PDB:4K33}.
FT   HELIX       735    737       {ECO:0000244|PDB:4K33}.
FT   HELIX       741    753       {ECO:0000244|PDB:4K33}.
SQ   SEQUENCE   806 AA;  87710 MW;  BC5EA75EA46F447E CRC64;
     MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS
     CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH
     FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG
     NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT
     YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP
     DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE
     EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK
     RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE
     GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN
     LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ
     VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW
     MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT
     HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS
     SSSGDDSVFA HDLLPPAPPS SGGSRT
//
